Wall Street Zen Downgrades MediWound (NASDAQ:MDWD) to Strong Sell

MediWound (NASDAQ:MDWD) was downgraded by equities researchers at Wall Street Zen from a “sell” rating to a “strong sell” rating in a research note issued on Saturday.

A number of other research analysts also recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of MediWound in a research report on Friday, July 17th. Oppenheimer reaffirmed an “outperform” rating and set a $30.00 price objective (down from $32.00) on shares of MediWound in a research report on Friday. Finally, HC Wainwright reiterated a “buy” rating and set a $36.00 price objective on shares of MediWound in a research note on Thursday, May 28th. Two equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $33.00.

MediWound Price Performance

Shares of MediWound stock opened at $13.56 on Friday. The firm has a market cap of $174.25 million, a P/E ratio of -7.53 and a beta of 0.15. MediWound has a fifty-two week low of $13.40 and a fifty-two week high of $20.30. The business has a 50-day moving average price of $14.35 and a 200 day moving average price of $15.96.

MediWound (NASDAQ:MDWD) last issued its earnings results on Thursday, August 13th. The biopharmaceutical company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.76) by ($0.01). MediWound had a negative return on equity of 47.24% and a negative net margin of 170.10%.The firm had revenue of $3.09 million during the quarter, compared to analyst estimates of $2.59 million. As a group, equities research analysts anticipate that MediWound will post -2.31 earnings per share for the current year.

Insider Buying and Selling at MediWound

In related news, Director David Morton Fox acquired 3,537 shares of the firm’s stock in a transaction dated Monday, June 1st. The stock was acquired at an average cost of $14.11 per share, for a total transaction of $49,907.07. Following the completion of the acquisition, the director directly owned 22,283 shares of the company’s stock, valued at approximately $314,413.13. The trade was a 18.87% increase in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Corporate insiders own 9.20% of the company’s stock.

Institutional Investors Weigh In On MediWound

Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Rhumbline Advisers raised its position in MediWound by 4.4% in the first quarter. Rhumbline Advisers now owns 11,316 shares of the biopharmaceutical company’s stock worth $176,000 after acquiring an additional 481 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of MediWound by 69.1% during the 2nd quarter. Russell Investments Group Ltd. now owns 1,588 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 649 shares in the last quarter. BNP Paribas Financial Markets grew its stake in shares of MediWound by 90.4% in the 3rd quarter. BNP Paribas Financial Markets now owns 1,523 shares of the biopharmaceutical company’s stock worth $27,000 after purchasing an additional 723 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in shares of MediWound by 22.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 5,452 shares of the biopharmaceutical company’s stock worth $85,000 after purchasing an additional 999 shares during the last quarter. Finally, Quarry LP bought a new stake in shares of MediWound in the 4th quarter worth approximately $26,000. Institutional investors own 46.83% of the company’s stock.

MediWound Company Profile

MediWound Ltd. (NASDAQ: MDWD) is a biopharmaceutical company headquartered in Yavne, Israel, specializing in the development and commercialization of innovative enzymatic therapies for burn and wound management. Since its establishment, the company has focused on advancing proteolytic enzyme technology to address critical needs in debridement and tissue repair. MediWound operates research and development facilities in Israel and maintains commercial offices in the United States to support its global market presence.

The company’s lead product, NexoBrid®, is an enzyme-based debriding agent designed to selectively remove burn eschar without harming viable tissue.